Jpmorgan Chase & CO Evogene Ltd. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Evogene Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 39,430 shares of EVGN stock, worth $24,840. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,430
Previous 64,594
38.96%
Holding current value
$24,840
Previous $54,000
46.3%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding EVGN
# of Institutions
32Shares Held
4.08MCall Options Held
23KPut Options Held
0-
Silverarc Capital Management, LLC3.09MShares$1.94 Million0.78% of portfolio
-
Morgan Stanley New York, NY284KShares$178,9500.0% of portfolio
-
Eidelman Virant Capital117KShares$73,7100.07% of portfolio
-
Lpl Financial LLC Fort Mill, SC66.8KShares$42,1060.0% of portfolio
-
Ubs Group Ag62.5KShares$39,3710.0% of portfolio
About Evogene Ltd.
- Ticker EVGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,202,000
- Market Cap $26M
- Description
- Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding ...